(EMAILWIRE.COM, April 10, 2019 ) The global medical aesthetics market is projected to reach USD 17.07 billion by 2023 from USD 9.42 billion in 2017, at a CAGR of 10.6% during the forecast period

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=885

As of 2017, Allergan, plc (Ireland), Alma Lasers, Ltd. (Israel), Anika Therapeutics (US), Cutera, Inc. (US), Cynosure (US), El.En. S.p.A. (Italy), Fotona d.o.o. (Slovenia), Nestlé S.A. (Switzerland), Johnson & Johnson (US), Merz Pharma GmbH & Co. KGaA (Germany), Medytox, Inc. (South Korea), Sientra, Inc. (US), Sinclair Pharma PLC (UK), Syneron Medical, Ltd. (US), and Valeant Pharmaceuticals International, Inc. (US) were the key players in the global medical aesthetics market.

These companies adopted product launches, enhancements, and product approvals; acquisitions; partnerships and collaborations; and expansions as their key growth strategies in the past four years.

The growing adoption of minimally invasive and noninvasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, the availability of technologically advanced & user-friendly products, and the increasing demand for aesthetic treatments among men are the key factors driving the growth of this market.

Speak to Our Expert @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=885

On the other hand, market growth is limited to a certain extent by factors such as the clinical risks and complications associated with medical aesthetic procedures and the increasing availability and adoption of alternative beauty and cosmetic products.